CRISPR GENOMIC CURE MARKET ANALYSIS

The global CRISPR genomic cure market size is expected to reach US$ 11.71 Bn by 2030, from US$ 3.18 Bn in 2023, at a CAGR of 20.5% during the forecast period. CRISPR is a revolutionary gene-editing technology that has the potential to cure a wide range of diseases, including cancer, HIV, and sickle cell anemia. The market is being driven by the increasing demand for personalized medicine, the rising prevalence of chronic diseases, and the growing government support for gene-editing research.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a genomic editing technology that enables precise changes to be made to DNA. The CRISPR genomic editing cure market has seen tremendous growth in recent years as scientists explore new therapeutic applications for various genetic diseases. CRISPR allows existing genetic material to be modified or corrected at a specific location and offers promising potential as a cure for conditions caused by mutations or changes in single or multiple genes. With ongoing clinical trials and research, CRISPR technology could transform genetic medicine and help treat previously incurable conditions like sickle cell disease, cystic fibrosis and several types of cancer.

Global CRISPR Genomic Cure Market Regional Insights

• North America is expected to be the largest market for CRISPR genomic cure during the forecast period, accounting for over 45.0% of the market share in 2022. The growth of the market in North America is attributed to the early adoption of new technologies in the region and the presence of a large number of pharmaceutical and biotechnology companies.
• European market is expected to be the second-largest market for CRISPR genomic cure, accounting for over 30.3% of the market share in 2022. The growth of the market in Europe is attributed to the increasing government support for gene-editing research and the presence of a large number of academic institutions.
• Asia Pacific market is expected to be the fastest-growing market for CRISPR genomic cure, with a CAGR of over 25.6% during the forecast period. The growth of the market in Asia Pacific is attributed to the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and the growing government support for gene-editing research.

Figure 1. Global CRISPR Genomic Cure Market Share (%), by Region, 2023

To learn more about this report, request sample copy

Analyst View

• The global CRISPR genomic cure market is driven by advances in CRISPR delivery systems and Cas nucleases that have made gene editing more precise and efficient for therapeutic applications. Rising public and private investments to accelerate research and development activity provide a big growth opportunity. However, challenges around immune response, and off-target editing, remain restrain factors hindering clinical translation. Progress in nanoparticle-mediated delivery methods and novel gene regulation tools could help address some of the technical limitations, which in turn provide exciting opportunities. Overall, the market is poised for strong growth over the long run as this disruptive technology moves closer to delivering life-changing medicines.

Global CRISPR Genomic Cure Market Drivers

• Precision and Versatility: CRISPR-Cas9 technology offers precise and efficient gene editing capabilities. It allows scientists to target and modify specific genes within an organism's genome, enabling potential cures for various genetic diseases. This precision and versatility have attracted significant attention and investment in the field.
• Potential for Treating Genetic Diseases: CRISPR-based genomic cures hold immense promise for treating a wide range of genetic diseases, including those that were previously considered untreatable. By correcting or modifying faulty genes responsible for genetic disorders, CRISPR offers the potential for transformative therapies and personalized medicine.
• Increasing Prevalence of Genetic Disorders: The prevalence of genetic disorders worldwide is significant, with millions of individuals affected by various conditions. These disorders often result in significant morbidity and mortality. The need for effective treatments has driven the interest in CRISPR-based genomic cures as a potential solution. For instance, in April 2021, the Centers for Disease Control and Prevention (CDC) reported that Down syndrome affects nearly 6,000 babies born in the U.S. annually, which is one in every 700 babies, and nearly 23,000-29,000 children suffer in India from Down syndrome annually, which is one in every 831.
• Rising Investment and Research Activities: The CRISPR technology has attracted substantial investment from both the public and private sectors. Funding has been directed towards research and development of CRISPR-based therapies, fueling advancements and accelerating the translation of these technologies into clinical applications. For instance, in February 2022, Synthego, the genome engineering company, announced it had raised $200 million of growth capital, including a Series E financing led by Perceptive Advisors, to accelerate the field of CRISPR-based medicines.

Global CRISPR Genomic Cure Market Opportunities

• Development of Targeted Therapies: CRISPR technology allows for precise and targeted gene editing, offering opportunities to develop therapies that specifically address the underlying genetic cause of a disease. This opens up possibilities for highly effective treatments with minimal off-target effects.
• Expansion to Rare Diseases: CRISPR-based genomic cures offer a viable solution for rare genetic diseases that have limited treatment options. These diseases often affect small patient populations, but the high unmet medical need and potential for personalized medicine make them attractive targets for CRISPR-based therapies.
• Advancements in Oncology: CRISPR presents opportunities in the field of oncology by enabling the development of novel cancer therapies. Gene editing can be utilized to target cancer-causing mutations, enhance the body's immune response against tumors, or develop more effective drug delivery systems. These approaches hold promise for improved cancer treatments and better patient outcomes. For instance, in March 2021, Dublin-based ERS Genomics granted CRISPR-Cas9 patent to a Japanese biotech start-up, Setsuro Tech. Setsuro Tech is developing cell and animal models based on this technology, which in turn is expected to increase the adoption of CRISPR-Cas9 technology in the country, leading to significant revenue generation in the near future.
• Gene Therapy Enhancements: CRISPR technology can be integrated with existing gene therapy approaches, enhancing their effectiveness. For example, CRISPR can be used to modify patient-derived cells ex vivo before reinfusion, allowing for targeted gene correction or disruption. This combination of CRISPR and gene therapy has the potential to enhance the success rate of treatments and expand their applicability.

Global CRISPR Genomic Cure Market Trends

• Increasing Clinical Trials: The number of clinical trials utilizing CRISPR-based genomic therapies has been steadily rising. Researchers are conducting trials to evaluate the safety and efficacy of CRISPR technologies in treating various genetic disorders and cancers. This trend highlights the growing interest and investment in translating CRISPR from the laboratory to clinical applications. For instance, the first trial in the U.S. to test a CRISPR-made cancer therapy was launched in 2019 at the University of Pennsylvania. The study, funded in part by the NCI (National Cancer Institute), is testing a type of immunotherapy in which patients own immune cells are genetically modified to better see and kill their cancer.
• Expansion of Indications: Initially, CRISPR-based therapies focused on monogenic diseases, where a single gene mutation causes the disorder. However, there is a trend towards exploring CRISPR's potential in treating complex diseases with multifactorial genetic components. Researchers are investigating the application of CRISPR in areas such as cardiovascular diseases, neurodegenerative disorders, and infectious diseases. For instance, in July 2022, a U.K. charity (The British Heart Foundation) provided US$36 million to an international team to develop innovative gene-editing treatments for inherited heart diseases. Recent gene editing techniques, particularly the CRISPR technology, have offered several opportunities to combat cardiovascular disease.
• Advancements in Delivery Systems: Effective delivery of CRISPR components to target cells remains a challenge. Researchers are actively developing and optimizing various delivery systems, such as viral vectors, lipid nanoparticles, and non-viral delivery methods, to enhance the efficiency and safety of CRISPR-based therapies. Advances in delivery systems are crucial for the successful translation of CRISPR technologies into clinical practice.
• Intellectual Property Landscape: The intellectual property landscape surrounding CRISPR technologies has been a subject of intense interest and legal disputes. Patents and licensing agreements related to CRISPR have significant implications for commercialization efforts and market dynamics. The market environment and the involvement of various stakeholders will be shaped by the ongoing legal battles and the resolution of patent disputes.

Global CRISPR Genomic Cure Market Restraints

• Off-Target Effects and Safety Concerns: CRISPR-Cas9 gene editing technology, while highly precise, can still have off-target effects, leading to unintended changes in the genome. Ensuring the safety and minimizing off-target effects of CRISPR-based therapies is a significant challenge that needs to be addressed to build confidence in their clinical applications.
• Delivery Challenges: Efficient and targeted delivery of CRISPR components to the desired cells and tissues remains a hurdle. The delivery systems need to be optimized to enhance efficiency, minimize immune response, and ensure the effective delivery of CRISPR tools to the target site. Developing reliable delivery methods for different tissues and organs is crucial for successful clinical applications.
• Regulatory Framework and Ethical Considerations: The ethical implications of CRISPR technology, particularly in germ line editing, raise complex questions and require careful consideration. Regulatory frameworks need to address these ethical concerns while providing a clear pathway for the development and use of CRISPR-based therapies. Striking the right balance between innovation and responsible use is critical for the market's growth.
• Intellectual Property Challenges: The CRISPR field has seen patent disputes and complex licensing agreements that can create uncertainties for companies and researchers. Intellectual property challenges can hinder the progress of research and development, potentially limiting the availability of CRISPR-based therapies and impacting the market's growth.

Figure 2. Global CRISPR Genomic Cure Market Share (%), by Application, 2023

To learn more about this report, request sample copy

Recent Developments

New product launches

• On June 8, 2023, Parse Biosciences, a leading provider of accessible and scalable single-cell sequencing solutions, announced the launch of CRISPR Detect, enabling single-cell pooled CRISPR screens at unprecedented scale.
• In January 2021, QIAGEN, a provider of molecular testing solutions, announced the launch of the QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions, which allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.
• In June 2020, Merck KGaA, a leading science and technology company, and 10x Genomics, Inc., a single-cell and spatial genomics technology company, announced that they had developed a powerful new option for biological experiments.

Collaboration and agreements

• On October 3, 2023, Regeneron Pharmaceuticals, Inc., a biotechnology company, and Intellia Therapeutics, Inc., a biotechnology company, announced an expanded research collaboration to develop additional in vivo CRISPR-based gene editing therapies focused on neurological and muscular diseases.
• In October 2021, Merck KGaA announced that its Life Science business sector had signed an agreement licensing its patented CRISPR-Cas9 technology to Cellecta, Inc., a functional genomics products and services provider based in Mountain View, California, U.S.
• In January 2020, ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property (IP), announced it had signed an agreement with New England Biolabs (NEB), a global leader in the discovery and production of enzymes for molecular biology applications, granting NEB rights to sell CRISPR/Cas9 tools and reagents.

Top companies in Global CRISPR Genomic Cure Market

• Merck KGaA
• Thermo Fisher Scientific Inc.
• Origene Technologies, Inc.
• New England Biolabs
• Intellia Therapeutics, Inc.
• GenScript
• GeneCopoeia, Inc.
• Cellectis
• Mammoth Biosciences
• Precision Biosciences, Inc.
• Synthego Corporation
• CRISPR Therapeutics
• Horizon Discovery Group plc
• Lonza Group Ltd.
• Takara Bio Inc.

*Definition: The global CRISPR genomic cure market refers to the commercial sector involved in the development, production, and distribution of therapeutic products and services based on CRISPR-Cas9 gene editing technology. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a revolutionary gene editing tool that allows scientists to precisely modify DNA sequences, offering immense potential for treating genetic diseases. The market encompasses various stakeholders, including biotechnology companies, pharmaceutical companies, research institutions, and investors, who are actively engaged in advancing CRISPR-based therapies for clinical applications. These therapies aim to correct or modify faulty genes responsible for inherited disorders, potentially providing curative treatments for a wide range of genetic diseases.